Morphology of myeloproliferative neoplasms

Myeloproliferative neoplasms (MPN) are a group of clonal haematological malignancies first described by Dameshek in 1957. The Philadelphia-negative MPN that will be described are polycythaemia vera (PV), essential thrombocythaemia (ET), pre-fibrotic myelofibrosis and primary myelofibrosis (PMF). The blood and bone marrow morphology are essential in diagnosis, for WHO classification, establishing a baseline, monitoring response to treatment and identifying changes that may indicate disease progression. The blood film changes may be in any of the cellular elements. The key bone marrow features are architecture and cellularity, relative complement of individual cell types, reticulin content and bony structure. Megakaryocytes are the most abnormal cell and key to classification, as their number, location, size and cytology are all disease-defining. Reticulin content and grade are integral to assignment of the diagnosis of myelofibrosis. Even with careful assessment of all these features, not all cases fit neatly into the diagnostic entities; there is frequent overlap reflecting the biological disease continuum rather than distinct entities. Notwithstanding this, an accurate morphologic diagnosis in MPN is crucial due to the significant differences in prognosis between different subtypes and the availability of different therapies in the era of novel agents. The distinction between reactive and MPN is also not always straightforward and caution needs to be exercised given the prevalence of triple negative MPN. Here we describe the morphology of MPN including comments on changes with disease evolution and with treatment.

Automated summary

Myeloproliferative neoplasms (MPN) are a group of clonal haematological malignancies. Diagnosis and classification of MPN rely on blood and bone marrow morphology, with key features including architecture, cellularity, cell types, reticulin content, and presence of megakaryocytes. Accurate morphologic diagnosis is crucial due to prognostic differences and varying therapies. Differentiating reactive conditions and MPN can be challenging, especially in triple negative MPN cases.